Cohance Lifesciences Limited (BOM:543064)
India flag India · Delayed Price · Currency is INR
549.10
+5.55 (1.02%)
At close: Dec 4, 2025

Cohance Lifesciences Company Description

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.

The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals.

It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025.

The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Cohance Lifesciences Limited
Country India
Founded 1989
Industry Pharmaceutical Preparations
Employees 1,212
CEO Vetukuri Venkata Naga Kali Vara Raju

Contact Details

Address:
A-Wing, Galaxy Towers
Hyderabad, 500081
India
Phone 91 40 2354 9414
Website cohance.com

Stock Details

Ticker Symbol 543064
Exchange Bombay Stock Exchange
Fiscal Year April - March
Reporting Currency INR
SIC Code 2834

Key Executives

Name Position
Vetukuri Venkata Naga Kali Vara Raju Chief Executive Officer
Himanshu Agarwal Chief Financial Officer
Cyndrella Carvalho Head of Investor Relations